Skip to content
MARKETS / NASDAQ / NTRB
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · SMALL CAP

NutriBand Inc. NTRB

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.0M
▼ 4.8% YoY
$-8.2M
$-5.1M
In brief

What this company does

Our primary business is the development of a portfolio of transdermal pharmaceutical products. The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Our principal offices are located in Orlando, Florida, and our subsidiary, Pocono Pharmaceuticals, has a manufacturing facility in Cherryville, North Carolina. Our lead product under development is AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with our AVERSA™ abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches.

Written from the business description in Nutriband Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 29 April 2026. Every sentence was checked against that document before publication.

Growth
USD 2.0M
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.0 · Net income -8.2
0.8M1.6M-4.0M-8.0M2016201720182019202020212022202320242025
Compound annual growth
−0.7%
+16.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +16.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−404 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -408.4% · Net -404.1%
-500%-1000%2016201720182019202020212022202320242025
ROE
FY2025 · ROE -125.6%
-1000%-2000%-3000%2016201720182019202020212022202320242025

Each USD of equity lost 126 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -5.1
-2M-4M2016201720182019202020212022202320242025

Total assetsUSD 7.5M
EquityUSD 6.7M
CashUSD 4.6M
Current ratio6.36×

Equity funds 88% of total assets.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.00.00.00.00.00.0··
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
Income tax $B··········
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0··−0.0··
EPS, diluted $−2.58−0.99−0.69−0.53−0.80−0.51−0.50−0.62−0.14−0.01
Dividend / sh $··········
Payout %··········
ROE %−125.6−162.9−73.1−43.9−65.1−80.5−211.0−263.7−3695.2−2599.2
Shares out B0.010.010.010.010.010.010.010.010.020.02

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 48 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 45 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsJanuary 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2015

Share this section

Download image